Barr PM, Smith S, Roschewski M, O'Brien SM, et al. Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. Leuk Lymphoma 2022 Feb 24:1-5. doi: 10.1080/10428194.2022.2043301.
PMID: 35200084